Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
2018 ◽
Vol 151
(2)
◽
pp. 257-263
◽
William P. Tew
◽
Michael W. Sill
◽
Joan L. Walker
◽
Angeles Alvarez Secord
◽
Albert J. Bonebrake
◽
...
2012 ◽
Vol 125
(2)
◽
pp. 367-371
◽
Don S. Dizon
◽
John A. Blessing
◽
Richard T. Penson
◽
Richard D. Drake
◽
Joan L. Walker
◽
...
2012 ◽
Vol 125
(3)
◽
pp. 635-639
◽
Michael A. Gold
◽
William E. Brady
◽
Heather A. Lankes
◽
Peter G. Rose
◽
Joseph L. Kelley
◽
...
2019 ◽
Vol 152
(3)
◽
pp. 548-553
◽
Ursula A. Matulonis
◽
Michael W. Sill
◽
Vicky Makker
◽
David G. Mutch
◽
Jay W. Carlson
◽
...
2014 ◽
Vol 133
(3)
◽
pp. 433-438
◽
Ronald D. Alvarez
◽
Michael W. Sill
◽
Susan A. Davidson
◽
Carolyn Y. Muller
◽
David P. Bender
◽
...
2014 ◽
Vol 132
(3)
◽
pp. 526-530
◽
Lainie P. Martin
◽
Michael Sill
◽
Mark S. Shahin
◽
Matthew Powell
◽
Paul DiSilvestro
◽
...
2007 ◽
Vol 2007
◽
pp. 82-83
David Kushner
◽
Ryan Spencer
1989 ◽
Vol 161
(2)
◽
pp. 309-312
◽
Gregory P. Sutton
◽
John A. Blessing
◽
Neil Rosenshein
◽
Guy Photopulos
◽
Philip J. DiSaia
2015 ◽
Vol 137
◽
pp. 24
◽
K.N. Moore
◽
M. Sill
◽
M.E. Tenney
◽
C.J. Darus
◽
D. Griffin
◽
...
Close
Export Citation Format
Close
Share Document
Close